skip to main |
skip to sidebar
Blog Archive
-
▼
2007
(88)
-
▼
September
(32)
- GlucoLight, Patent for Sentris-100™ Blood Glucose ...
- Biodel , U.S. Patent Covering Lead Product Candida...
- Innocoll , phase 2 clinical trials for the treatme...
- Theratechnologies' Glucagon-like Peptide-1 (GLP-1)...
- Nastech Pharmaceutical, Phase 2 Clinical Trial for...
- Incyte , Proof-of-Concept Results For INCB13739, 1...
- PuriCore's Vashe, Wound Therapy System
- CytRx, iroxanadine for the treatment of diabetic f...
- Biodel has expanded its two ongoing pivotal Phase ...
- Pfizer and EFSD, New Research Program Focused on C...
- Cytomedix, FDA Clearance For AutoloGel
- CoMentis, Diabetic Macular Edema Clinical Trial wi...
- Generex , paper entitled Ii-Key/MHC class II epito...
- Biodel , VIAject(TM) Phase II Meal Study Data
- Oculus Innovative Sciences, Phase II Study for Mic...
- Metabasis Therapeutics, Promising Preclinical Resu...
- MicroIslet and Progenitor Cell Therapy , Agreement...
- Isis, Collaboration With Ortho-McNeil, for the Dis...
- Pharmacopeia, Positive Results from Phase 1 Multip...
- Diabetes Detection, second-generation pager protot...
- XOMA, Phase 1 European Trial in Diabetes for XOMA ...
- Living Cell Technologies, Ethics Approval for Diab...
- Phosphagenics, Phase 2 TPM/Insulin clinical trial
- Quigley Pharma’s Phase IIb Clinical Study of QR-33...
- XTL Biopharmaceuticals , Phase IIb Clinical Trial ...
- Sernova, Sertoli Cells Successfully Engineered to ...
- OSI Pharmaceuticals, Positive Results from a Metfo...
- Alba Therapeutics, IND for Beta Cell Preservation ...
- PhytoMedical , Preliminary Research Results For Ne...
- Isis Pharmaceuticals Phase 1 Study of ISIS 325568 ...
- Kane Biotech, diabetic foot ulcers's application
- GlucoLight, first hypoglycemic clamping study of i...
CytRx, iroxanadine for the treatment of diabetic foot ulcers Clinical Trial Updates
Sept. 24, 2007--CytRx Corporation (NASDAQ:CYTR) a biopharmaceutical company engaged in the development and commercialization of human therapeutics, today provided updates to its designs for its clinical trials with its orally-administered molecular chaperone-based drug candidates arimoclomol for the treatment of patients with ALS and in stroke recovery, and iroxanadine for the treatment of diabetic foot ulcers... CytRx's Press Release -
Sept. 24, 2007--CytRx Corporation (NASDAQ:CYTR) a biopharmaceutical company engaged in the development and commercialization of human therapeutics, today provided updates to its designs for its clinical trials with its orally-administered molecular chaperone-based drug candidates arimoclomol for the treatment of patients with ALS and in stroke recovery, and iroxanadine for the treatment of diabetic foot ulcers... CytRx's Press Release -
